ReviewCancer medicine2025
Phase Separation of PHLDB2 Drives EMT and Tumor Progression in Triple-Negative Breast Cancer.
Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.British journal of haematology · 2026Article
- Phase Separation of PHLDB2 Drives EMT and Tumor Progression in Triple-Negative Breast Cancer.Cancer medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLiquid-liquid phase separation (LLPS) has emerged as a critical mechanism underlying oncogenic signaling and transcriptional regulation; however, its involvement in triple-negative breast cancer (TNBC) remains largely unknown. The pleckstrin homology-like domain family B member 2 (PHLDB2) has been implicated in cytoskeletal organization and cell migration, but its role in phase separation-mediated tumor progression has not been explored.
methodsWe conducted an integrative multi-omics analysis combining transcriptomic profiling, bioinformatic modeling, and molecular biology experiments to elucidate the function of PHLDB2 in TNBC. Expression, mutation, and copy number variation of phase separation-related genes were analyzed using TCGA, METABRIC, and GTEx datasets. PHLDB2 knockdown and overexpression models were established in MDA-MB-231 and HCC38 cells to assess cell proliferation, epithelial-mesenchymal transition (EMT), and extracellular matrix (ECM)-related pathways. Immunofluorescence and fluorescence recovery after photobleaching (FRAP) assays were performed to evaluate the phase separation properties of PHLDB2. In vivo, xenograft and pulmonary metastasis models were used to validate the effects of Phldb2 knockdown on TNBC growth and metastasis.
resultsPHLDB2 was significantly upregulated in TNBC and correlated with poor clinical prognosis. Gene ontology and KEGG analyses revealed its enrichment in ECM-receptor interaction and focal adhesion pathways. PHLDB2 knockdown inhibited cell proliferation and migration, suppressed EMT by upregulating E-cadherin and downregulating N-cadherin, vimentin, Snail, and MMP-2. PONDR analysis identified extensive intrinsically disordered regions (IDRs) within PHLDB2, and FRAP assays confirmed its ability to form dynamic, reversible condensates consistent with LLPS. In vivo, Phldb2 depletion markedly reduced tumor growth and pulmonary metastases and prolonged survival in TNBC-bearing mice.
conclusionOur findings demonstrate that PHLDB2 promotes TNBC progression by mediating ECM remodeling and EMT activation through phase separation-driven signal organization. These results establish PHLDB2 as a novel phase separation-dependent oncogenic regulator and highlight its potential as a prognostic biomarker and therapeutic target in TNBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.